Ipamorelin vs GHRP-2: Ghrelin-Receptor Selectivity, Structure and Which to Use

Both compounds act at GHS-R1a, the growth hormone secretagogue receptor for which ghrelin is the endogenous ligand, so the target is not what distinguishes them — selectivity is, and that is essentially the whole basis for choosing between them. GHRP-2 derives from the enkephalin-derived GHRP-6 template and is described as affecting prolactin, cortisol and appetite signalling alongside growth hormone; ipamorelin, by contrast, was characterised in animal work as producing a comparatively isolated GH response. The decisive question when comparing them is therefore whether that broader neuroendocrine activity would contaminate any of the endpoints you intend to measure.

Both are offered as freeze-dried powder, each lot with its own HPLC certificate — GHRP-2 in 10 and 5 mg vials, ipamorelin in 10, 5 and 2 mg vials — within our GHRPs and secretagogues category. Each one is a research chemical for in-vitro and preclinical laboratory use only.

The same pharmacophore, different termini

Set the two sequences side by side and the family resemblance stands out: D-phenylalanine and D-2-naphthylalanine appear in both, and both finish with Lys-NH2. Across this family, D-2-Nal is the residue that drives potency — the reason GHRP-2 outperforms the GHRP-6 template it was derived from — and the amide at the C-terminus eliminates the negative charge a free acid would carry, which assists receptor binding and blocks carboxypeptidase attack.

Where they part company is at the other end, and in length. GHRP-2 opens with D-alanine, an arrangement that impedes aminopeptidases, and carries tryptophan and alanine in the middle of a six-residue chain. Ipamorelin instead starts with Aib (alpha-aminoisobutyric acid), an amino acid not found in proteins, which simultaneously constrains the backbone's shape and resists proteases, and it fits the same pharmacophore into just five residues.

The upshot is that both are small, protease-tolerant peptides that are simple to synthesise, with ipamorelin the shorter and more rigidly held of the two. At 711.85 g/mol against 817.97 g/mol, a milligram of ipamorelin also delivers about 15 percent more molecules than a milligram of GHRP-2 — sufficient to distort any comparison set up by weight.

Selectivity: the substantive difference

The receptor sits within a neuroendocrine system that also touches appetite regulation, prolactin release and the hypothalamic–pituitary–adrenal axis. The earlier generation of GH secretagogues — GHRP-6, GHRP-2 and hexarelin — were reported to move ACTH, cortisol and prolactin as well as growth hormone, and in the GHRP-6 line to increase food intake as well.

Ipamorelin was developed and profiled with that background explicitly in view. The animal studies that introduced it emphasised a GH response unaccompanied by the prolactin and cortisol changes seen with its predecessors, and it is exactly this reported selectivity that made it a routine tool for isolating GHS-R1a signalling from the surrounding endocrine noise.

Two qualifications. To begin with, these selectivity claims rest on cell and animal data and are comparative rather than absolute: "relatively clean" is not the same as "without off-target activity at any concentration". Secondly, the wider profile of GHRP-2 is not a defect. If your research question concerns how secretagogue signalling intersects with the HPA axis or with appetite regulation, the broader compound is the one that yields data, and ipamorelin would produce none.

Place in the literature and what each is best used for

GHRP-2 occupies a notable position in the history of this field: it was instrumental in establishing that the growth hormone secretagogue receptor is a target distinct from the GHRH receptor, work done before ghrelin had been identified as its natural ligand. That history makes it a useful reference agonist — for characterising binding at GHS-R1a, for calibrating inositol-phosphate and calcium-flux assays, and, alongside hexarelin and GHRP-6, for anchoring potency rankings within the family. It also has a regulatory past in some countries as a diagnostic agent in GH secretion testing, though that applies to a regulated pharmaceutical product rather than to research-grade powder.

Ipamorelin serves a different function. It is the compound of choice when an experiment needs GHS-R1a activated without accompanying signals, which is why it appears more often than GHRP-2 as the secretagogue partner in combination work — one receptor from each limb of the somatotropic axis. For those designs we offer CJC-1295 co-formulated with ipamorelin as well as ipamorelin co-formulated with GHRP-2, plus CJC-1295 (No DAC) alone for single-agent arms. The GH secretagogue landscape article charts the whole family.

Matching the compound to the research question

Choose ipamorelin when the readout must stay clean

If you are measuring growth hormone release, downstream IGF-1, or signalling at GHS-R1a itself, and a shift in prolactin, cortisol or feeding would confound the result, ipamorelin's reported selectivity is exactly the property you want. It is likewise the appropriate secretagogue arm in a two-receptor combination design, where an off-target signal could not be assigned to one compound or the other.

Choose GHRP-2 when the broader profile is the subject

Where the research concerns the relationship between secretagogue signalling and prolactin release, appetite pathways or the HPA axis, GHRP-2 stimulates the very systems being measured. It is also the more suitable reference point for ranking potency within the family, and for reproducing the older secretagogue literature, much of which used it.

Use both when selectivity itself is the variable

The pair constitutes a neat two-point series for probing selectivity: one shared receptor, one shared pharmacophore, two different reported breadths of off-target activity. Running them together with a full endocrine panel — not GH alone — is the standard way to test a selectivity claim instead of taking it on trust. GHRP-6 or hexarelin lengthens the series further; see the ipamorelin vs GHRP-6 and hexarelin vs ipamorelin comparisons.

Differences in handling, reconstitution and storage

Both are short peptides with an amidated C-terminus and unnatural residues, and neither is difficult to work with: no acyl chains, no free thiols, no reactive linkers. The same routine covers both — store sealed freeze-dried vials in the freezer, bring them to room temperature before the stopper is pierced so that no condensation forms on chilled powder, introduce the diluent along the vial wall, let it dissolve without agitation, and split the stock into aliquots to avoid repeated freeze–thaw. The reconstitution and storage guides give the specifics.

One point does differ and deserves mention. Because GHRP-2 carries a tryptophan at position 4 — the residue most readily photo-oxidised in peptides — it degrades in light, and does so faster in water where dissolved oxygen or metal traces are present. Keep GHRP-2 solutions in the dark and make them up reasonably fresh. Ipamorelin, lacking tryptophan, is comparatively light-tolerant, though its naphthylalanine is aromatic too, so prolonged bright light is worth avoiding with either peptide.

The following is bench arithmetic and not a usage recommendation: 2 mL of diluent added to a 5 mg vial produces 2.5 mg/mL, that is 2,500 mcg/mL, so 250 mcg occupies 0.1 mL. Because roughly 15 percent separates the two molecular weights, identical mass concentrations are not identical molarities; set up and report potency comparisons in molar units.

Purity, identity and certificate checks

Ask for the lot-specific certificate with each vial and verify three things: HPLC purity with the chromatogram shown, a mass-spec figure matching the theoretical weight (ipamorelin 711.85 g/mol, GHRP-2 817.97 g/mol), and a lot number matching the label. Two further checks are specific to these peptides. Both carry a C-terminal amide, and the corresponding free acid weighs 1 Da less, comes off the column near the main peak and acts as a different molecule at the receptor — so confirm the amidation rather than assuming it. Both also contain D-amino acids, and epimerisation in synthesis produces same-mass diastereomers that MS cannot distinguish, which is why a chromatogram with one narrow peak carries more weight here than the purity figure does. In older GHRP-2 material, a minor peak 16 Da heavier than the parent may indicate oxidised tryptophan. Our COA guide sets out what a complete certificate contains.

Regulatory position

Both peptides are sold as research chemicals for laboratory use and not for human consumption. Neither has approval as a medicine in the United States. GHRP-2 has been regulated as a diagnostic agent in certain jurisdictions, but that status belongs to a regulated pharmaceutical product and not to research-grade powder. Our growth and performance research overview provides the wider context.